Magnesium Sulfate in Bariatric Surgery

Bariatric Surgery Candidate Clinical Trial

— MgSObs  

Official title:

"Evaluation of the Clinical Response to Magnesium Sulfate as an Adjuvant in Anesthesia in Bariatric Surgery"

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05843812
• Other study ID #: C.B/01-04-23
• Status: Active, not recruiting
• Start date: April 21, 2023
• Est. completion date: June 30, 2024

Study information

• Verified date: May 2023
• Source: Instituto Mexicano del Seguro Social
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Weight loss surgery, also known as bariatric surgery, has been around since the 1950s and since its inception has been shown to successfully achieve significant and sustainable weight loss in a large number of patients who undergo this intervention, as well , if a beneficial impact is observed in the management of metabolic disorders, such as type 2 diabetes mellitus and hyperlipidemia.

After bariatric surgery, patients are at risk of narcotic-related side effects.(2) Because of this, pain management strategies must be implemented to reduce the consumption of narcotic medications. Some studies have reported that a multimodal analgesic regimen can reduce the consumption of postoperative narcotics, as well as the therapy requirements to control postoperative nausea and vomiting.

It has also been reported that excess body mass is associated with changes in mineral levels in the body, particularly hypomagnesemia , a condition that is also common in hospitalized patients (Hansen & Bruserud 2018), and has a high incidence in the perioperative environment.

Magnesium sulfate (MgSO4) has multiple desirable effects in an anesthetic procedure. It is an antagonist of the N-methyl-d-aspartic acid (NMDA) receptor, which is why it produces an analgesic effect related to the prevention of central sensitization caused by peripheral tissue injury. In addition, other relevant clinical effects of MgSO4 have been reported in anesthesiology, such as its effect as a CNS depressant, modulation of the hemodynamic response, reduction of the intraoperative requirements of anesthetics, analgesics, and muscle relaxants. As well as the potentiation of the effect of non-depolarizing muscle relaxants.

The role of magnesium in the body and its pharmacological properties continue to be studied and knowledge of its pharmacological, clinical and physiological characteristics has become essential for the anesthesiologist.

There are no previous studies that allow establishing an optimal therapeutic scheme considering all the perioperative clinical effects of MgSO4 and that evaluate the role of genetic variability in pain perception and response to treatment in bariatric surgery.

Description:

A total of 104 participants, men and women over the age of 18, scheduled for bariatric surgery, will be included. After accepting and signing the informed consent, a brief preoperative clinical history will be taken, a peripheral blood sample will be taken to determine preoperative serum Ca2+ and Mg2+, and to analyze polymorphic variants related to pain perception and the pharmacokinetics of analgesics. The clinical effect of MgSO4 on analgesia (EVAD), hemodynamic stability (BP and HR), intubation conditions, and satisfaction with anesthetic recovery will be evaluated. The presence of adverse reactions to anesthesia (nausea, vomiting, chills, pruritus, urinary retention, arrhythmias, laryngeal or bronchial spasm) and total doses of drugs used during the perioperative period will be recorded. All patients will undergo a standard pre, trans and postoperative protocol and according to the treatment received with MgSO4 as part of their anesthetic management or not, they will be assigned to the corresponding group (MgSO4/ No MgSO4). All the data will be collected in an Excel database, for subsequent analysis in SPSS.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 104
• Est. completion date: June 30, 2024
• Est. primary completion date: December 31, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

• Patients scheduled for bariatric surgery under general o anesthesia at Hospital universitario de la Facultad de Medicina de la Universidad Autonoma de Coahuila

• Physical state ASA 2 y 3

• Acceptance and signing of the informed consent.

Exclusion Criteria:

• Treatment with calcium or magnesium channel blockers

• Drug use or alcoholism referred by the patient in the questioning

• Neurological diseases

• Myopathy

• Intracardiac block

• Renal insufficiency

• Liver failure

• Pregnancy

• Hematological disorders

• Contraindications to the use of magnesium sulfate (hypersensitivity to the active principle or to any of the excipients, concomitant use with quinidine derivatives, tachycardia, heart failure, myocardial injury, infarction).

Elimination criteria:

• Survey with incomplete data corresponding to the study variables.

• Revocation of informed consent or decision to withdraw by of the patient.

• Loss to follow-up

Related Conditions & MeSH terms

• Anesthesia and Analgesia
• Bariatric Surgery Candidate
• Magnesium Sulfate

Intervention

Drug:
• Magnesium Sulfate 10 MG/ML
Patients who received preoperative infusion with magnesium sulfate as part of their anesthetic management

Locations

Country	Name	City	State
Mexico	Lilia Edith Luque-Esparza	Gómez Palacio	DGO

Sponsors (1)

Lead Sponsor	Collaborator
Instituto Mexicano del Seguro Social

Country where clinical trial is conducted

Mexico, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Serum magnesium	Serum magnesium concentrations(mg / dL)	Before IV infusion of MgS04 and 24 hours after coming out of anesthesia
Other	Intracellular magnesium	Magnesium content in erythrocyte cells	Before IV infusion of MgS04 and 24 hours after coming out of anesthesia
Primary	Changes in postoperative analgesia over 24 hours	Postoperative pain intensity reported by the participant using the visual analog scale after bariatric surgery	[Time Frame: 15 minutes after coming out of anesthesia, 2, 4, 6 and 24 hours after coming out of anesthesia]
Primary	Time to first request for pain reliever	Time (minutes) to request analgesia after coming out of bariatric surgery	[Time Frame: 24 hours after departure from anesthesia]
Primary	Hemodynamic stability	Changes in heart rate (beats per minute) and mean systemic arterial pressure (mmHg) intraoperatively after or during bariatric surgery were combined to report hemodynamic stability.; Measurements of heart rate and mean arterial pressure will be added to arrive at a reported value (hemodynamic stability: yes or no).; Changes in heart rate (beats per minute) and mean systemic arterial pressure (mmHg) less than 20% with respect to baseline values will be considered as criteria for hemodynamic stability, without the need to administer atropine, ephedrine or other positive chronotropic agents and / or vasoactive agents.	[Time Frame: 180 minutes intraoperatively]
Primary	Interaction with neuromuscular blockers (BNM): Onset time	Parameters measured per train of four after administration of the non-depolarizing muscle relaxant according to the parameters established in the current guidelines for good clinical research practices in pharmacodynamic studies of neuromuscular blocking agents II: - Onset time (OT): Time elapsed from the administration of BNM to obtaining a depression in the monitored motor response of between 80 to 100% with the T1 stimulus pattern of TOF.	[Time Frame: 180 minutes intraoperatively]
Primary	Interaction with neuromuscular blockers (BNM):Clinical effect time	Parameters measured per train of four after administration of the non-depolarizing muscle relaxant according to the parameters established in the current guidelines for good clinical research practices in pharmacodynamic studies of neuromuscular blocking agents II: - Clinical effect time: Time elapsed from administration of BNM until 25% is recovered in the monitored motor response measured with TOF as T1> 25% or ST> 25%.	[Time Frame: 180 minutes intraoperatively]
Primary	Interaction with neuromuscular blockers (BNM): Recovery index (RI)	Parameters measured per train of four after administration of the non-depolarizing muscle relaxant according to the parameters established in the current guidelines for good clinical research practices in pharmacodynamic studies of neuromuscular blocking agents II: - Recovery index (RI): Time elapsed between recovery of 25% and 75% of T1 from TOF.	[Time Frame: 180 minutes intraoperatively]
Secondary	Adverse reactions to magnesium sulfate	Adverse reactions to the perioperative administration of parenteral magnesium sulfate that derive from magnesium poisoning or alterations in the administration site.; Administration site alterations (injection site pain, hypothermia, vasodilation with a sensation of heat).; Nervous system (loss of tendon reflex, headache, dizziness, coma, drowsiness and confusion, CNS depression, respiratory paralysis).; Cardiovascular system (circulatory collapse, arrhythmias, cardiac arrest).; Respiratory system (respiratory depression secondary to neuromuscular block).; Gastrointestinal system (nausea and vomiting).; Musculoskeletal and connective tissue system (muscle weakness).; Others (problems with speech, vision, excessive sweating, thirst, or others not reported).	[Time Frame: From the start of the magnesium sulfate infusion until 24 hours after leaving anesthesia]
Secondary	Adverse reactions to anesthesia	Side and adverse effects associated with the use of anesthetic drugs.; Nausea, vomiting, itching, chills, urinary retention, arrhythmias, laryngeal or bronchial spasm.	[Time Frame: 180 minutes intraoperatively up to 24 hours after discharge from anesthesia]
Secondary	Number of participants carrying polymorphisms related to perioperative clinical response to magnesium sulfate	Determination of polymorphisms related to the pharmacokinetics of opioids (gene CYP3A4/*16, CYP3A4/*1B), the NMDA receptor (GENE NR1/GRIN1, NR2/GRIN2A, NR2B/GRIN2B, NR3A/GRIN3A, NR3B/GRIN3B), and magnesium transporters (gene CNNM2, TRPM6, SLC41A1, SLC41A2).	[Time Frame: During the 2-year duration of the study]
Secondary	Conditions for endotracheal intubation	Evaluation of the conditions for orotracheal intubation. Use a qualitative scoring system. The factors that are taken into consideration are: ease of laryngoscopy, position and / or movement of the vocal cords and reaction to intubation.	5 minutes after the administration of BNM
Secondary	Consumption of intraoperative analgesics	Consumption of analgesics (µg of fentanyl) intraoperatively in induction and / or maintenance in each group of patients.	180 minutes intraoperatively
Secondary	Postoperative analgesic consumption	Consumption of opioid analgesics (evaluated as mg morphine equivalents) postoperatively	From exit from anesthesia up to 24 hours
Secondary	Consumption of neuromuscular relaxant	Consumption of neuromuscular relaxant (mg of cisatracurium) intraoperatively in intubation and / or maintenance after / during bariatric surgery, in each study group.	180 minutes intraoperatively
Secondary	Hypnotic use	Hypnotic consumption (mg of propofol) intraoperatively in intubation and / or maintenance after / during bariatric surgery, in each study group.	180 minutes intraoperatively
Secondary	Satisfaction in recovery from anesthesia	The overall satisfaction of the patients was evaluated the day after surgery using the IOWA scale (Dissatisfied: -3-2-1, Satisfied + 1 + 2 + 3) after bariatric surgery.	24 hours after departure from anesthesia